__NUXT_JSONP__("/drugs/Dexrazoxane", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:"dexrazoxane hydrochloride",conditionIndication:"Savene is indicated for the treatment of anthracycline extravasation.",inn:b,marketingAuthorisationDate:"2006-07-27 00:00:00",marketingAuthorisationHolder:"Clinigen Healthcare B.V.",medicineName:"Savene",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fsavene"}],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"24584-09-6",chebiId:"CHEBI:50223",chemicalFormula:"C11H16N4O4",definition:"A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.",fdaUniiCode:"048L81261F",identifier:"C1333",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C360"],synonyms:["(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)","2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI)","2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)","2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)","2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)","ADR-529","DEXRAZOXANE",a,"ICRF-187","Razoxane (+)-form","Soluble ICRF (L-isomer)",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FDexrazoxane",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Dexrazoxane","dexrazoxane","2021-10-30T13:31:43.523Z")));